Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $78.42 USD
Change Today +1.04 / 1.34%
Volume 3.7M
As of 4:15 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

medtronic plc (MDT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/15 - $79.50
52 Week Low
04/14/14 - $55.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDTRONIC PLC (MDT)

medtronic plc (MDT) Details

Medtronic plc, a healthcare solutions company, provides medical technologies, services, and solutions worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company also offers a portfolio of surgical, respiratory and monitoring, and vascular therapies solutions, as well as medical supplies. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

49,247 Employees
Last Reported Date: 11/21/14
Founded in 1949

medtronic plc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Executive Vice President and Group President ...
Total Annual Compensation: $675.1K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic plc (MDT) Key Developments

Medtronic plc's Protege GPS Self-Expanding Peripheral Stent System Receives FDA Approval for Use in Treating Iliac Artery Stenosis

Medtronic plc announced that its Protege(TM) GPS(TM) self-expanding peripheral stent system has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of stenotic lesions of the common and external iliac arteries. The results demonstrated the safety and effectiveness of the Protege GPS peripheral stent system in the treatment of stenotic lesions of the common and external iliac arteries. The prospective, multi-center, non-randomized clinical study demonstrated 95.8% nine-month primary patency (the ability for the treated artery to remain open) by Kaplan-Meier analysis and 98.6% freedom from target vessel revascularization (no repeat procedure). Iliac stenosis occurs when plaque builds up in the iliac artery, which can block the blood supply to the entire leg. As a result, patients with iliac artery stenosis can experience pain that can limit mobility. The Protege GPS self-expanding peripheral stent system allows physicians to treat iliac artery lesions and restore blood flow with large diameter stents through a low, 6F profile delivery system. The stent is cut from a nitinol tube into an open lattice design and has tantalum radiopaque markers at the proximal and distal ends of the stent. Upon deployment, the stent achieves its predetermined diameter and exerts a constant, outward force to restore patency.

Medtronic to Initiate Clinical Study of Drug-Filled Stent Following Preclinical Results

Medtronic plc unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology. The preclinical data showed controlled and efficacious drug elution into the arterial wall without a polymer carrier, while reducing diameter stenosis and achieving complete stent coverage quickly without inflammation. Based on these results, Medtronic plans to initiate a clinical trial in the coming months. The first global DFS study will be conducted at multiple sites in geographies including Australia and Brazil. The clinical study will enroll 100 patients and will evaluate late lumen loss as measured by quantitative coronary angiography. The innovative DFS is built on the proven platform of the Resolute Integrity DES with Continuous Sinusoid Technology (a unique Medtronic method of stent manufacturing that molds one single strand of wire into a sinusoidal wave enabling a continuous range of motion), as well as the next-generation Resolute Onyx DES with CoreWire Technology that allows it to have a denser core metal surrounded by a cobalt alloy outer layer. The new DFS features a novel tri-layer wire design, which allows the inner most core layer to be removed, so that the hollow strut lumen functions as an internal drug reservoir. Drug is eluted from the core upon implantation through abluminal side holes on the surface of the stent, which allows for controlled, polymer-free drug elution over a desired period of time directly into the arterial wall to potentially avoid chronic inflammation and adverse vascular responses.

Medtronic plc Unveils Two-Year Data from the High Risk Study of the CoreValve U.S. Pivotal Trial

Medtronic plc unveiled new, highly anticipated two-year data from the High Risk Study of the CoreValve U.S. Pivotal Trial, which continued to show superior survival benefit at two years for transcatheter aortic valve replacement (TAVR) with the CoreValve(R) System compared to patients who underwent surgical aortic valve replacement (SAVR). The CoreValve US Pivotal High Risk Study is the first and only head-to-head study to show statistically significant survival differences favoring TAVR in aortic stenosis patients who are considered high risk for surgery. Presented as a late-breaking clinical trial at the 64th Annual Scientific Session of the American College of ardiology (ACC.15), the two-year outcomes from the CoreValve High Risk Study found that the rate of all-cause mortality was significantly lower in TAVR patients than in the SAVR patients with the absolute difference in all-cause mortality increasing between the two groups from 4.8% at one year to 6.5% at two years.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $78.42 USD +1.04

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $166.05 USD +2.55
Abbott Laboratories $47.08 USD +0.30
Astellas Pharma Inc ¥1,988 JPY +38.00
Baxter International Inc $68.76 USD +0.21
Sanofi €92.70 EUR +1.01
View Industry Companies

Industry Analysis


Industry Average

Valuation MDT Industry Range
Price/Earnings 24.8x
Price/Sales 4.4x
Price/Book 3.8x
Price/Cash Flow 31.7x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at